Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Adams

Showing results (111-120 of 143) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 19, 2024
Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluationRomain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
BMC Bioinformatics|December 16, 2014
COMBINE archive and OMEX format: one file to share all information to reproduce a modeling projectFrank T Bergmann, Richard Adams, Stuart Moodie, et al.
Trials|August 31, 2017
A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trialNick J Battersby, Mit Dattani, Sheela Rao, et al.
BMJ Open|November 10, 2025
Personalising anal cancer radiotherapy dose (PLATO): protocol for a multicentre integrated platform trialRussell Frood, Alexandra Gilbert, Duncan Gilbert, et al.
Journal of the National Cancer Institute|December 19, 2019
HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal TrialPaul R Barber, Gregory Weitsman, Katherine Lawler, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 9, 2024
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trialAlexander D Murphy, Catharine Porter, Ann White, et al.
The Lancet. Oncology|August 8, 2017
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trialsHarpreet S Wasan, Peter Gibbs, Navesh K Sharma, et al.
Eclinicalmedicine|July 6, 2023
Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trialSomnath Mukherjee, Christopher N Hurt, Richard Adams, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 29, 2025
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trialAlexander D Murphy, Catharine Porter, Ann White, et al.
BMC Cancer|October 25, 2024
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitorsMargherita Carucci, Andrew Clamp, Cong Zhou, et al.
Pageof 15

Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|January 19, 2024
Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluationRomain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
BMC Bioinformatics|December 16, 2014
COMBINE archive and OMEX format: one file to share all information to reproduce a modeling projectFrank T Bergmann, Richard Adams, Stuart Moodie, et al.
Trials|August 31, 2017
A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trialNick J Battersby, Mit Dattani, Sheela Rao, et al.
BMJ Open|November 10, 2025
Personalising anal cancer radiotherapy dose (PLATO): protocol for a multicentre integrated platform trialRussell Frood, Alexandra Gilbert, Duncan Gilbert, et al.
Journal of the National Cancer Institute|December 19, 2019
HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal TrialPaul R Barber, Gregory Weitsman, Katherine Lawler, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 9, 2024
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trialAlexander D Murphy, Catharine Porter, Ann White, et al.
The Lancet. Oncology|August 8, 2017
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trialsHarpreet S Wasan, Peter Gibbs, Navesh K Sharma, et al.
Eclinicalmedicine|July 6, 2023
Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trialSomnath Mukherjee, Christopher N Hurt, Richard Adams, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 29, 2025
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trialAlexander D Murphy, Catharine Porter, Ann White, et al.
BMC Cancer|October 25, 2024
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitorsMargherita Carucci, Andrew Clamp, Cong Zhou, et al.
Pageof 15